Upstream Bio, Inc.
Upstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue fell 17.5%, EPS grew 1.35% and free cash flow grew 9.33%, each against the same quarter a year earlier.
Follow UPB
Upstream Bio, Inc. (UPB) EV/Sales
As of 16 October 2026, Upstream Bio, Inc. (UPB) trades at a EV/Sales of −35.1×. Over the past ten years it has ranged from −159× (March 2025) to 495× (January 2026); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 393× | — |
| FY2024 | −104× | — |
| FY2023 | −64.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 36.8× | (37.07%) |
| Mar 2026 | 58.5× | (85.10%) |
| Dec 2025 | 393× | 71.18% |
| Sep 2025 | 229× | 217.33% |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. | −35.1× |
| TRDA Entrada Therapeutics, Inc. compare | −8.3× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −4.0× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.5× |
| ADCT ADC Therapeutics SA compare | 1.5× |
| ACOG Alpha Cognition Inc. compare | 9.0× |
| YARW Yarrow Bioscience, Inc compare | 124× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)